Retailers sue Pfizer over delay in Lipitor sales
Lipitor had peak sales of nearly USD 13 billion a year several years ago.
Washington: Alleging drug maker Pfizer Inc of delaying sales of cheap generic versions of the cholesterol drug Lipitor, five US drug and grocery chains have filed a lawsuit against the company, a news wire reported on Saturday.
Lipitor, the world's top-selling drug ever, had peak sales of nearly USD 13 billion a year several years ago. Sales dropped sharply after it got US generic competition on November 30.
The lawsuit, filed Thursday by Walgreen Co, the Kroger Co and three other retailers in US District Cfourt in Trenton, claims generics should have been available nearly two years earlier, when Lipitor's original patent expired.
The suit accuses Pfizer of patent fraud as well as "illegal, anti-competitive conduct" with generic drugmaker Ranbaxy Laboratories of India to block other generic drugmakers from selling versions of Lipitor, called atorvastatin calcium, until recently.
The suit also accuses New York-based Pfizer of making deals with companies that manage prescription benefits, giving them big discounts on brand-name Lipitor in exchange for those companies limiting sales of generic versions. Generic pills generally bring pharmacies higher profit margins than brand-name medicines do.
Pfizer denies the lawsuit claims and said yesterday that it "will defend itself vigorously." A spokesman for Ranbaxy said the company had not been served with the lawsuit and has a policy against commenting on pending litigation.
The plaintiffs, which include Safeway Inc, Supervalu Inc and HEB Grocery Co LP, claim the original patent for the active ingredient in Lipitor expired in March 2010 and that Pfizer fraudulently got the US Patent and Trademark Office to grant a follow-on patent that extended Pfizer's monopoly on Lipitor sales.
According to Pfizer, Lipitor has additional patents that run until 2017, in addition to the patent in question in the lawsuit.
With Agency Inputs